Antibody to Hepatitis C Virus ELISA Kit

Name: Antibody to Hepatitis C Virus ELISA Kit
SKU: DEIA062
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum, plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

Anti-HCV ELISA is an enzyme-linked immunosorbent assay (ELISA) for qualitative detection of antibodies to hepatitis C virus in human serum or plasma.

Contents of Kit

MICROWELL PLATE: 1×96wells, 8×12/12×8-well per plate. Blank microwell strips fixed on white strip holder. The plate is sealed in aluminum pouch with desiccant. Each well contains recombinant HCV antigens. The microwell strips can be broken to be used separately. Place unused wells or strips in the provided plastic sealable storage bag together with the desiccant and return to 2-8°C. Once open, stable for one month at 2-8°C
NEGATIVE CONTROL: 1×0.2ml per vial preserv.0.1% ProClin^TM 300. Blue-colored liquid filled in a vial with green screw cap. Protein-stabilized buffer tested non-reactive for HCV antibodies. Ready to use as supplied. Once open, stable for one month at 2-8°C.
POSITIVE CONTROL: 1×0.2ml per vial preserv.0.1% ProClin^TM 300. Red-colored liquid filled in a vial with red screw cap. Anti-HCV antibodies diluted in protein-stabilized buffer. Ready to use as supplied. Once open, stable for one month at 2-8°C.
HRP-CONJUGATE: 1×13ml per vial preserv.0.1% ProClin^TM 300. Red-colored liquid in a white vial with red screw cap. Horseradish peroxidase-conjugated rabbit anti-human IgG antibodies. Ready to use as supplied. Once open, stable for one month at 2-8°C.
SPECIMEN DILUENT: 1×13ml per vial preserv.0.1% ProClin^TM 300. Green-colored in a vial with blue screw cap. Serum base, casein, and sucrose solution.
WASH BUFFER: 1×50ml per bottle DILUTE BEFORE USE! detergent Tween-20. Colorless liquid filled in a clear bottle with white screw cap. PH 7.4, 20 × PBS. The concentrate must be diluted 1 to 20 with distilled/ deionized water before use. Once diluted, stable for one week at room temperature, or for two weeks when stored at 2-8°C.
CHROMOGEN SOLUTION A: 1×8ml per vial. Colorless liquid filled in a white vial with green screw cap. Urea peroxide solution. Ready to use as supplied. Once open, stable for one month at 2-8°C.
CHROMOGEN SOLUTION B: 1×8ml per vial. Colorless liquid filled in a black vial with black screw cap.TMB solution (Tetramethyl benzidine dissolved in citric acid). Ready to use as supplied. Once open, stable for one month at 2-8°C.
STOP SOLUTION: 1×8ml per vial. Colorless liquid in a white vial with yellow screw cap. Diluted sulfuric acid solution (0.5M H₂SO₄). Ready to use as supplied. Once open, stable for one month at 2-8°C.

Storage

The components of the kit will remain stable through the expiration date indicated on the label and package when stored between 2-8°C, do not freeze. To assure maximum performance of this Anti-HCV ELISA, during storage, protect the reagents from contamination with microorganism or chemicals.

Sensitivity

Clinical Sensitivity: Among 480 clinical hepatitis C patients confirmed positive by RIBA 3.0, 480 were positive when tested with this Anti-HCV ELISA. The sensitivity was 100%.
No cross reactivity observed with samples from patients infected with HAV, HBV, HIV, CMV and TP. No interference was observed from rheumatoid factors up to 2000U/ml.
The performance characteristics of this assay are unaffected from elevated concentrations of bilirubin, hemoglobin, and triolein.
Same day and frozen specimens have been tested to check for interferences due to collection and storage.

General Description

Hepatitis C virus (HCV) is an envelope, single stranded positive sense RNA (9.5 kb) virus belonging to the family of Flaviviridae. Six major genotypes and series of subtypes of HCV have been identified. Isolated in 1989, HCV is now recognized as the major cause for transfusion associated non-A, non-B hepatitis. The disease is characterized with acute and chronic form although more than 50% of the infected individuals develop severe, life threatening chronic hepatitis with liver cirrhosis and hepatocellular carcinomas. Since the introduction in 1990 of anti-HCV screening of blood donations, the incidence of this infection in transfusion recipients has been significantly reduced. The first generation of HCV ELISAs showed limited sensitivity and specificity and was produced using recombinant proteins complementary to the NS4 (c100-3) region of the HCV genome as antigens. Second generation tests, which included recombinant / synthetic antigens from the Core (c22) and nonstructural regions NS3 (c33c, c100-3) and NS4 (c100-3, c200) resulted in a remarked improvement in sensitivity and specificity. Clinical studies show that significant amount of HCV infected individuals develop antibodies to NS5 non-structural protein of the virus. For this, the third generation tests include antigens from the NS5 region of the viral genome in addition to NS3 (c200), NS4 (c200) and the Core (c22). Third generation tests have improved sensitivity and shorten the time between infection with HCV and the appearance of detectable antibodies (window period) to 60 days.

Citations

Have you cited DEIA062 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Pathways involved in viral oncogenesis: New perspectives from virus-host protein interactomics

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Authors: Kori, Medi; Arga, Kazim Yalcin

Abstract

Oncogenic viruses are among the apparent causes of cancer-associated mortality. It was estimated that 12% to 15% of human malignancies are linked to oncoviruses. Although modernist strategies and traditional genetic studies have defined host-pathogen interactions of the oncoviruses, their host functions which are critical for the establishment of infection still remain mysterious. However, over the last few years, it has become clear that infections hijack and modify cellular pathways for their benefit. In this context, we constructed the virus-host protein interaction networks of seven oncoviruses (EBV, HBV, HCV, HTLV-1, HHV8, HPV16, and HPV18), and revealed cellular pathways hijacking as a result of oncogenic virus infection. Several signaling pathways/processes such as TGF-beta signaling, cell cycle, retinoblastoma tumor suppressor protein, and androgen receptor signaling were mutually targeted by viruses to induce oncogenesis. Besides, cellular pathways specific to a certain virus were detected. By this study, we believe that we improve the understanding of the molecular pathogenesis of viral oncogenesis and provide information in setting new targets for treatment, prognosis, and diagnosis.

A qualitative study of facilitators and barriers to participate in a needle exchange program for women who inject drugs

HARM REDUCTION JOURNAL

Authors: Falk, Malin Varma; Stromdahl, Susanne; Ekstrom, Anna Mia; Kaberg, Martin; Karlsson, Niklas; Dahlborn, Helena; Hammarberg, Anders

Abstract

Background Women who inject drugs (WWID) show higher levels of injecting risk behaviour compared to men, putting them at risk of contracting HIV and hepatitis C (HCV). Compared to men, WWID are also less present in harm reduction programs such as needle exchange programs (NEP). The aim of this study is to investigate reasons for, and barriers to, participation in NEP among WWID in Sweden, and to identify measures that could be taken to strengthen the program and increase participation among WWID. Method In-depth interviews (IDIs) were conducted with 20 WWID who had participated in the Stockholm NEP for at least six months and was over 18 years old. IDIs were audio recorded and transcribedet verbatim. Qualitative content analysis was used to identify themes. Results The need for sterile injection equipment was identified as the main driver to join and remain in the NEP program. Continuous participation in the NEP was further driven by easy access to a multitude of health-related services. The most valued service was the sexual and reproductive health services (SRHR), allowing participants to access contraceptives, cervical cancer screening and sexually transmitted infections testing (STI-testing). NEP staffs' respectful treatment of participants further contributed to program participation. However, participants also expressed a number of concerns around NEP participation, which created barriers to joining. These included losing custody or visitation rights to children, male partner jealousy and violence, unwillingness to spend time in the waiting area and fear of receiving positive HIV/HCV test results. Practical barriers included limited opening hours and travel distance to the NEP. To strengthen the program, most participants requested additional SRHR services. Most participants also proposed some form of "women only" access to the NEP, to strengthen the feeling of the NEP as a safe space. Conclusion This study identified factors that may increase uptake of NEP among WWID. Additional SRHR services and "women only" access are recommended to be implemented and evaluated as part of NEP. These findings may inform and improve the current scale-up of NEPs in Sweden to ensure equal access to services.